第九届全国免疫学学术大会

2014-10-18 00:00:01

中国山东济南

Backgroud&Aim:Increasing evidence had demonstrated that Immunoscore(IS)has an advantage over or may compensate for the currently used tumour staging methods in a variety of tumours;however,IS in hepatocellular carcinoma(HCC)remains unreported.Methods:IS was performed on serial sections from two HCC cohorts and was compared with current tumour staging methods.Results:In both cohorts 1(n=90)and 2(n=21),althougli positive correlations existed between the CD3~+or CD8~+cells in tumours and OS,a large variation existed in the use of one immune cell as an indicator.We then investigated whether the combined analysis(IS)could improve the prediction.The patients were divided into CD3~(HiHi)plus CD8~(HiHi)(high density in both centre tumour[CT]and invasive margin[IM],IS=4,the highest score)groups,CD3~(LoLo)plus CD8~(LoLo)(low density in both regions,IS=0,the lowest score)groups and intermediates(IS=l-3).Our results demonstrated that the ISs of 21HCC sections could be divided into four groups:IS-0(n=7),IS-1(n=1),IS-2(n=7)and IS-4(n=6)without IS-3.A strong association was identified between a higher IS(IS-4 and IS-2)and longer disease-free survival.When we used IS-2 as a cut-off value,the TNM-ⅠorⅢand BLCL-A,B or C stage patients could be divided into two groups:the patients with IS≥2 in each stage clearly exhibited longer survival compared with the same stage patients with IS<2.Conclusion:These findings suggest that IS is a promising prognostic indicator for the current classifications in HCC.